RESUMEN
Although a ubiquitous natural phenomenon, the onset and subsequent process of surface wave breaking are not fully understood. Breaking affects how steep waves become and drives air-sea exchanges1. Most seminal and state-of-the-art research on breaking is underpinned by the assumption of two-dimensionality, although ocean waves are three dimensional. We present experimental results that assess how three-dimensionality affects breaking, without putting limits on the direction of travel of the waves. We show that the breaking-onset steepness of the most directionally spread case is double that of its unidirectional counterpart. We identify three breaking regimes. As directional spreading increases, horizontally overturning 'travelling-wave breaking' (I), which forms the basis of two-dimensional breaking, is replaced by vertically jetting 'standing-wave breaking' (II). In between, 'travelling-standing-wave breaking' (III) is characterized by the formation of vertical jets along a fast-moving crest. The mechanisms in each regime determine how breaking limits steepness and affects subsequent air-sea exchanges. Unlike in two dimensions, three-dimensional wave-breaking onset does not limit how steep waves may become, and we produce directionally spread waves 80% steeper than at breaking onset and four times steeper than equivalent two-dimensional waves at their breaking onset. Our observations challenge the validity of state-of-the-art methods used to calculate energy dissipation and to design offshore structures in highly directionally spread seas.
RESUMEN
Osteoarthritis (OA) was previously thought of as 'wear and tear' as humans age, however there is increasing evidence to support an inflammatory theory. The nucleotide-binding and oligomerization domain-like receptor containing protein 3 (NLRP3) inflammasome has been implicated in the pathogenesis of a number of arthritic disorders, producing proinflammatory cytokines and degradative enzymes such as Interleukin-1 beta (IL-1ß), Tumour necrosis factor alpha (TNF-α) and Matrix metalloproteinase-3 (MMP-3) which drive cartilage degeneration and synovial inflammation. This review aims to summarise the evidence of NLRP3 involvement in OA. Currently, treatment options focus on management of the disease and to date there is no cure. The development of novel biomarkers for OA could improve diagnosis, treatment and management. Importantly, this review provides detail on the involvement of the NLRP3 inflammasome in OA pathology and how its members could act as potential biomarkers to assist clinical decisions.
Asunto(s)
Manejo de la Enfermedad , Proteína con Dominio Pirina 3 de la Familia NLR/metabolismo , Osteoartritis/metabolismo , Biomarcadores/metabolismo , Humanos , Osteoartritis/diagnóstico , Osteoartritis/terapiaRESUMEN
The overall objective of OrBiTo, a project within Innovative Medicines Initiative (IMI), is to streamline and optimize the development of orally administered drug products through the creation and efficient application of biopharmaceutics tools. This toolkit will include both experimental and computational models developed on improved understanding of the highly dynamic gastrointestinal (GI) physiology relevant to the GI absorption of drug products in both fasted and fed states. A part of the annual OrBiTo meeting in 2015 was dedicated to the presentation of the most recent progress in the development of the regulatory use of PBPK in silico modeling, in vivo predictive dissolution (IPD) tests, and their application to biowaivers. There are still several areas for improvement of in vitro dissolution testing by means of generating results relevant for the intraluminal conditions in the GI tract. The major opportunity is probably in combining IPD testing and physiologically based in silico models where the in vitro data provide input to the absorption predictions. The OrBiTo project and other current research projects include definition of test media representative for the more distal parts of the GI tract, models capturing supersaturation and precipitation phenomena, and influence of motility waves on shear and other forces of hydrodynamic origin, addressing the interindividual variability in composition and characteristics of GI fluids, food effects, definition of biorelevant buffer systems, and intestinal water volumes. In conclusion, there is currently a mismatch between the extensive industrial usage of modern in vivo predictive tools and very limited inclusion of such data in regulatory files. However, there is a great interest among all stakeholders to introduce recent progresses in prediction of in vivo GI drug absorption into regulatory context.
Asunto(s)
Tracto Gastrointestinal/metabolismo , Preparaciones Farmacéuticas/química , Preparaciones Farmacéuticas/metabolismo , Administración Oral , Biofarmacia/métodos , Absorción Gastrointestinal/fisiología , Humanos , Modelos Biológicos , SolubilidadRESUMEN
As the demand for evidence to support the value of genetic counseling increases, it is critical that reporting of genetic counseling interventions in research and other types of studies (e.g. process improvement or service evaluation studies) adopt greater rigor. As in other areas of healthcare, the appraisal, synthesis, and translation of research findings into genetic counseling practice are likely to be improved if clear specifications of genetic counseling interventions are reported when studies involving genetic counseling are published. To help improve reporting practices, the National Society of Genetic Counselors (NSGC) convened a task force in 2015 to develop consensus standards for the reporting of genetic counseling interventions. Following review by the NSGC Board of Directors, the NSGC Practice Guidelines Committee and the editorial board of the Journal of Genetic Counseling, 23 items across 8 domains were proposed as standards for the reporting of genetic counseling interventions in the published literature (GCIRS: Genetic Counseling Intervention Reporting Standards). The authors recommend adoption of these standards by authors and journals when reporting studies involving genetic counseling interventions.
Asunto(s)
Comités Consultivos , Asesoramiento Genético/normas , Informe de Investigación/normas , Sociedades Médicas , Femenino , Humanos , Masculino , Estados UnidosRESUMEN
Combined mental and physical stress is associated with exacerbated cortisol production which may increase risk for the progression of cardiovascular disease in individuals working in high-stress occupations (e.g., firefighters, military personnel, etc.). Carbohydrate (CHO) ingestion prior to physical stress may attenuate cortisol concentrations. This project was the first to investigate the effect of CHO ingestion on cortisol response from combined mental and physical stress. 16 men 21-30 years old were randomly assigned a 6.6% CHO beverage or non-CHO control 15 min prior to performing a dual-concurrent-stress challenge. This consisted of physical stress (i.e., steady state exercise) combined with computerized mental challenges. Blood was sampled 70, 40, and 15 min before exercise, immediately at onset of exercise, 10, 20, 30, 35 min during exercise, and 15, 30, 45, and 60 min after exercise. There was a significant main effect for treatment regarding mean cortisol concentrations (F=5.30, P=0.0219). The total area under curve for cortisol was less when CHO was ingested (T7=4.07, P=0.0048). These findings suggest that CHO ingestion immediately prior to combined mental and physical stress may attenuate cortisol responses.
Asunto(s)
Carbohidratos de la Dieta/farmacología , Ejercicio Físico/fisiología , Hidrocortisona/sangre , Estrés Fisiológico , Estrés Psicológico , Adulto , Bebidas , Estudios Cruzados , Método Doble Ciego , Prueba de Esfuerzo , Humanos , Masculino , Adulto JovenRESUMEN
Evaluation of clinical genetics services (CGS), including genetic counseling and genetic testing, has been problematic. Patient mortality and morbidity are unlikely to be directly improved by interventions offered in CGS. Patient-reported outcomes (PROs) are not routinely measured in CGS evaluation, but this may change as patient-reported outcome measures (PROMs) become a key part of how healthcare services are managed and funded across the world. However, there is no clear consensus about which PROMs are most useful for CGS evaluation. This review summarizes the published research on how PROs from CGS have been measured and how patients may benefit from using those services, with a focus on patient empowerment. Many patient benefits (PROs) identified repeatedly in the research literature can be re-interpreted within a patient empowerment framework. Other important PROs identified include family functioning, social functioning, altruism, sense of purpose, enabling development of future research and treatment/participating in research. Well-validated measures are available to capture (dimensions of) patient empowerment. Although generic measures of family functioning are available, suitable measures capturing social functioning, development of future treatments, and altruism were not identified in this review. Patient empowerment provides one useful approach to measuring PROs from CGS.
Asunto(s)
Servicios Genéticos , Evaluación del Resultado de la Atención al Paciente , Participación del Paciente/psicología , Humanos , Encuestas y Cuestionarios , Resultado del TratamientoRESUMEN
The aim of this study was to develop a patient-reported outcome measure (PROM) for clinical genetics services. Previous research was used to develop a draft 84-item questionnaire, which was completed by 527 members of patient support groups. Responses were subjected to exploratory factor analysis (EFA). Parallel analysis was used to identify the number of factors to extract using oblique rotation. Twenty-four questions were selected to form the Genetic Counseling Outcome Scale (GCOS-24). Two hundred and forty-one patients completed a questionnaire pack before and after attendance at a genetics clinic that included the GCOS-24, and validated measures of health locus of control, perceived personal control, anxiety, depression, satisfaction with life and authenticity. Concurrent validity of the GCOS-24 was assessed using bivariate correlation. Sensitivity to change of the GCOS-24 was assessed using analysis of variance. EFA identified a single overarching construct consisting of seven dimensions. Internal consistency (α = 0.87) and test-retest reliability (r = 0.86) are good. The GCOS-24 shows convergent and divergent validities, and sensitivity to change over time with a medium-to-large effect size (Cohen's d = 0.70). The GCOS-24 has potential as a clinical genetics-specific PROM.
Asunto(s)
Asesoramiento Genético/métodos , Humanos , Evaluación de Resultado en la Atención de Salud , Psicometría/métodos , Encuestas y CuestionariosRESUMEN
Background: The second wave of coronavirus disease 2019 (COVID-19), dominated by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Beta variant, has been reported to be associated with increased severity in South Africa (SA). Objectives: To describe and compare clinical characteristics, management and outcomes of COVID-19 patients admitted to an intensive care unit (ICU) in SA during the first and second waves. Methods: In a prospective, single-centre, descriptive study, we compared all patients with severe COVID-19 admitted to ICU during the first and second waves. The primary outcomes assessed were ICU mortality and ICU length of stay (LOS). Results: In 490 patients with comparable ages and comorbidities, no difference in mortality was demonstrated during the second compared with the first wave (65.9% v. 62.5%, p=0.57). ICU LOS was longer in the second wave (10 v. 6 days, p<0.001). More female admissions (67.1% v. 44.6%, p<0.001) and a greater proportion of patients were managed with invasive mechanical ventilation than with non-invasive respiratory support (39.0% v. 14%, p<0.001) in the second wave. Conclusion: While clinical characteristics were comparable between the two waves, a higher proportion of patients was invasively ventilated and ICU stay was longer in the second. ICU mortality was unchanged.
RESUMEN
OBJECTIVE: Successful disease management requires effective surveillance. Slaughterhouse inspections provide opportunities to efficiently collect regular disease data from many animals across large areas. Toxoplasma is a cat-borne parasite that causes reproduction failure in sheep, although it is not visually detectable at slaughterhouses. Macroscopic sarcocystosis is a disease of sheep that is visually detectable at slaughter and is caused by parasites that share a similar biology with Toxoplasma. We investigated if sarcocystosis could act as a proximate measure for Toxoplasma exposure in sheep to facilitate its efficient surveillance at large scales. DESIGN/METHODS: We compared the presence of macroscopic sarcocystosis to Toxoplasma serostatus at the animal and farm levels. RESULTS: At the animal level, we found a weak association between Toxoplasma seropositivity and sarcocysts in the oesophagus (OR = 1.76 [95% CI: 1.17, 2.65; McFadden's R2 = 0.01]) but no association between Toxoplasma seropositivity and sarcocysts in skeletal muscles. At the farm level, the seroprevalence of Toxoplasma was strongly associated with oesophageal sarcocystosis prevalence (OR = 28.59 [95% CI: 13.07, 62.57; McFadden's R2 = 0.34]) but less strongly associated with sarcocystosis prevalence in skeletal muscles (OR = 7.91 [95% CI: 1.24, 50.39; McFadden's R2 = 0.02]). CONCLUSIONS: For Toxoplasma surveillance in sheep at the farm level, routine slaughter inspection and recording of macroscopic oesophageal sarcocystosis could be are liable and efficient proximate measure. The monitoring of oesophageal sarcocystosis may be a useful passive Toxoplasma surveillance tool for guiding the timing and location of other Toxoplasma detection methods to facilitate the management of Toxoplasma impacts within the sheep industry.
Asunto(s)
Enfermedades de los Gatos , Sarcocystis , Sarcocistosis/veterinaria , Enfermedades de las Ovejas , Toxoplasma , Animales , Gatos , Esófago , Estudios Seroepidemiológicos , OvinosRESUMEN
BACKGROUND: The exponential rise in people living longer but requiring residential care is adding pressure to already overstretched aged care nurses. Consequently, a person-centred care culture in residential care remains aspirational, rather than a reality. For nursing students in Australia and elsewhere, clinical placements in aged care facilities are under-utilised due to negative perceptions about the likelihood for learning. Creative strategies to engage students to safely challenge ageist thinking and to inspire enthusiasm for learning in this context are needed. OBJECTIVES: The purpose of this thematic review of the literature is to better understand challenges related to learning in aged care settings and identify innovative strategies to enhance nursing student learning experiences in residential aged care placements. REVIEW METHODS: A literature review was undertaken in 2019 using CINAHL, PUBMED, Elsevier, Medline, ProQuest and Google Scholar. The search was limited to papers that were peer reviewed, in English, and published between 2001 and the date of review (mid-2019) in order to situate the review in the new millennium. RESULTS: 47 articles and books were included in the review that introduce solutions and innovative strategies that could be used to improve students' attitudes to learning in aged care and from older people. The literature review was categorized into three main themes, including: barriers to working with older people; the need for pedagogical change to foster empathy; and innovative strategies to address barriers. CONCLUSION: These themes are useful to consider in designing engaging learning and teaching for nursing students to be effective in working in aged care.
Asunto(s)
Competencia Clínica , Empatía , Aprendizaje Basado en Problemas , Instituciones Residenciales/tendencias , Estudiantes de Enfermería/psicología , Anciano , Australia , Bachillerato en Enfermería , HumanosRESUMEN
OrBiTo was a precompetitive collaboration focused on the development of the next generation of Oral Biopharmaceutics Tools. The consortium included world leading scientists from nine universities, one regulatory agency, one non-profit research organisation, three small/medium sized specialist technology companies together with thirteen pharmaceutical companies. The goal of the OrBiTo project was to deliver a framework for rational application of predictive biopharmaceutics tools for oral drug delivery. This goal was achieved through novel prospective investigations to define new methodologies or refinement of existing tools. Extensive validation has been performed of novel and existing biopharmaceutics tools using historical datasets supplied by industry partners as well as laboratory ring studies. A combination of high quality in vitro and in vivo characterizations of active drugs and formulations have been integrated into physiologically based in silico biopharmaceutics models capturing the full complexity of gastrointestinal drug absorption and some of the best practices has been highlighted. This approach has given an unparalleled opportunity to deliver transformational change in European industrial research and development towards model based pharmaceutical product development in accordance with the vision of model-informed drug development.
Asunto(s)
Biofarmacia/métodos , Preparaciones Farmacéuticas/química , Administración Oral , Animales , Sistemas de Liberación de Medicamentos/métodos , Desarrollo de Medicamentos/métodos , Tracto Gastrointestinal/metabolismo , Humanos , Absorción Intestinal , Estudios ProspectivosRESUMEN
The full-genome sequences of strains chicken/Indonesia/Cilebut/010WJ/2015 and chicken/Indonesia/ITA/012WJ/1951, isolated in West Java, Indonesia, in 2015 and 1951, respectively, were examined. Chicken/Indonesia/Cilebut/010WJ/2015 (genotype VII) caused a 2015 disease outbreak in Indonesia, and chicken/Indonesia/ITA/012WJ/1951 (genotype VI) is used as a standard strain for challenge in Newcastle disease virus (NDV) vaccine trials.
RESUMEN
The impact of continuous sub-therapeutic chlortetracycline on community structure, composition and abundance of tetracycline resistance genes in the rat fecal community was investigated. Rats were fed a standard diet containing chlortetracycline at 15 microg g(-1) diet for 28 days, followed by 30 microg g(-1) diet to completion of the study on day-56. These levels are similar to those administered to swine during the grow-out phase. Sub-therapeutic chlortetracycline affected the fecal community as determined through change in the cultivable anaerobic community and through molecular-based analyses including denaturing gradient gel electrophoresis profiles of the variable 2-3 region community 16S rRNA genes over time and through comparative sequence analysis of 16S rRNA gene community libraries. Significant decreases in fecal phylotype diversity occurred in response to sub-therapeutic chlortetracycline, although total bacterial output remained constant over the entire feeding trial. Chlortetracycline at 15 microg g(-1) diet resulted in significant change in community composition, but only modest change to the fecal community structure in terms of the distribution of individual phylotypes among the major fecal lineages. Chlortetracycline at 30 microg g(-1) diet significantly altered the distribution of phylotypes among the major fecal lineages shifting the overall community such that Gram-negative phylotypes aligning within the phylum Bacteroidetes became the dominant lineage (>60% of total community). While chlortetracycline impacted both fecal community structure and composition, there was no significant effect on the abundance of community tetracycline resistance genes [tet(Q), tet(W), tet(O)] or on the emergence of a new putative tetracycline resistance gene identified within the fecal community. While sub-therapeutic chlortetracycline provides sufficient selective pressure to significantly alter the fecal community, the primary outcome appears to be the development of a community which may have a higher inherent tolerance to sub-therapeutic levels of chlortetracycline rather than an overgrowth of the tetracycline resistant bacteria already present within the community.
Asunto(s)
Alimentación Animal , Bacterias/efectos de los fármacos , Clortetraciclina/administración & dosificación , Ecosistema , Heces/microbiología , Resistencia a la Tetraciclina/genética , Animales , Antibacterianos/farmacología , Bacterias/clasificación , Bacterias/genética , Bacterias/crecimiento & desarrollo , Proteínas Bacterianas/genética , Clortetraciclina/farmacología , Recuento de Colonia Microbiana , Medios de Cultivo , Datos de Secuencia Molecular , Filogenia , Reacción en Cadena de la Polimerasa/métodos , ARN Ribosómico 16S/genética , Ratas , Ribosomas/metabolismo , Análisis de Secuencia de ADNRESUMEN
Infection with the cat-borne parasite Toxoplasma gondii has been detected in numerous Australian marsupials and can lead to severe disease (toxoplasmosis) in some cases. The seroprevalence of Toxoplasma on Kangaroo Island, South Australia has been reported to be higher than the South Australian mainland in macropods, cats, and sheep, suggesting an increased risk of infection on this island. However, Toxoplasma seroprevalence in small- and medium-sized terrestrial mammals was almost zero on the island and did not differ from that on the mainland. We surveyed Toxoplasma seroprevalence in koala (Phascolarctos cinereus) populations on the island and on the mainland and assessed their risk of infection and their role in the life cycle of Toxoplasma. All screened koalas from the island (n = 94) and the mainland (n = 63) were seronegative. This represents the largest Toxoplasma seroprevalence survey in this species and provided sufficient evidence to confidently demonstrate freedom from parasite exposure in both island and mainland populations at the time of the survey. Because koalas are extensively arboreal and predominately consume tree foliage, they appear to be at negligible risk of Toxoplasma infection. Furthermore, as koalas are rarely consumed by cats, we suggest that they have a minor role in the parasite's life cycle.
Asunto(s)
Phascolarctidae/parasitología , Toxoplasma/aislamiento & purificación , Toxoplasmosis Animal/epidemiología , Pruebas de Aglutinación/veterinaria , Animales , Anticuerpos Antiprotozoarios/sangre , Femenino , Islas/epidemiología , Masculino , Estudios Seroepidemiológicos , Australia del Sur/epidemiología , Toxoplasma/inmunologíaRESUMEN
Neospora caninum naturally infects many mammal species, but has not previously been demonstrated in birds. We examined sera for N. caninum antibodies from 200 outdoor chickens and from 200 chickens confined indoors in the state of Bahia, Brazil. Seroprevalence was greater in outdoor chickens (23.5% versus 1.5%, P<0.001). PCR testing for N. caninum was positive in six of 10 seropositive chickens. Amplicons from two of these were sequenced and had 97-98% nucleotide identity with N. caninum. This finding extends the list of intermediate hosts of N. caninum to include birds and may have important epidemiological consequences.
Asunto(s)
Anticuerpos Antiprotozoarios/sangre , Pollos/parasitología , Coccidiosis/transmisión , Neospora/fisiología , Crianza de Animales Domésticos/métodos , Animales , Secuencia de Bases , Enfermedades de las Aves/parasitología , Aves/parasitología , Brasil , Pollos/inmunología , ADN Protozoario/análisis , Reservorios de Enfermedades/parasitología , Técnica del Anticuerpo Fluorescente Indirecta , Datos de Secuencia Molecular , Neospora/genética , Neospora/inmunología , Estudios Seroepidemiológicos , Toxoplasma/inmunología , Toxoplasma/fisiologíaRESUMEN
Neospora caninum has recently been shown to be a cause of abortions of sheep in New Zealand. A commercially available enzyme-linked immunosorbent assay (ELISA) was validated for use in sheep with sera from experimentally infected sheep. A cut-off threshold was established that demonstrated sero-conversion between 7 and 14 days post-infection. Higher inocula led to earlier sero-conversion. This ELISA was applied to 640 sera collected from rams across New Zealand and 0.625% (+/-0.61%) (4/640) were shown to be serologically positive. The four positive sera were also demonstrated to be positive by indirect fluorescent antibody test (IFAT). The ELISA evaluated here lends itself more readily to large-scale investigations than IFAT. The low background of N. caninum infection in the New Zealand sheep population suggests that N. caninum abortions could be more easily diagnosed by serological means than in populations with higher background sero-prevalence.
Asunto(s)
Coccidiosis/veterinaria , Ensayo de Inmunoadsorción Enzimática/veterinaria , Neospora/aislamiento & purificación , Enfermedades de las Ovejas/diagnóstico , Enfermedades de las Ovejas/epidemiología , Animales , Anticuerpos Antiprotozoarios/sangre , Coccidiosis/diagnóstico , Coccidiosis/epidemiología , Ensayo de Inmunoadsorción Enzimática/métodos , Femenino , Técnica del Anticuerpo Fluorescente Indirecta/veterinaria , Masculino , Nueva Zelanda/epidemiología , Ovinos , Enfermedades de las Ovejas/parasitología , Factores de TiempoRESUMEN
The EU research initiative OrBiTo (oral biopharmaceutics tools) involving partners from academia, pharmaceutical industry, small medium enterprises and a regulatory agency was launched with the goal of improving tools to predict the absorption of drugs in humans and thereby accelerating the formulation development process. The OrBiTo project was divided into four work packages (WP), with WP2 focusing on characterization of drug formulations. The present work introduces the OrBiTo WP2 Decision Tree, which is designed to assist the investigator in choosing the most appropriate in vitro methods for optimizing the oral formulation design and development process. The WP2 Decision Tree consists of four stages to guide the investigator. At the first stage, the investigator is asked to choose the formulation type of interest. At the second stage, the investigator is asked to identify which type of equipment (compendial/modified/noncompendial) is preferred/available. At the third stage, characteristics of the active pharmaceutical ingredient (API) are evaluated and in the fourth stage of the decision tree, suitable experimental protocols are recommended. A link to the living Decision Tree document is provided, and we now invite the pharmaceutical sciences community to apply it to current research and development projects and offer suggestions for improvement and expansion.
Asunto(s)
Biofarmacia/métodos , Árboles de Decisión , Preparaciones Farmacéuticas/administración & dosificación , Administración Oral , Diseño de Fármacos , Industria Farmacéutica/métodos , Liberación de Fármacos , Humanos , Preparaciones Farmacéuticas/metabolismoRESUMEN
Whilst it is presumed that infection of pregnant cattle with Neospora caninum oocysts can provoke abortion and is the likely cause of epidemic abortion outbreaks, only two previous experiments have involved inoculation of pregnant cows with oocysts (and only one abortion was provoked in 22 pregnancies). Here, we describe the oral oocyst challenge of 18 cows synchronously bred and inoculated precisely at 70 (n=6), 120 (n=6) and 210 (n=6) days in pregnancy with a nominal dose of 40,000 oocysts. Only one abortion occurred (at the 120 days challenge) which could be definitively ascribed to N. caninum and no transplacental infection (TPI) was detected in any of the other 11 calves born in the 70 and 120 day challenge groups. In contrast, 4/5 live calves born to cattle challenged at 210 days were transplacentally infected. When cows which had transplacentally infected their calves in the first pregnancy were rebred, no TPI occurred. The results show that the timing of challenge influences clinical and parasitological outcomes and that cattle in late pregnancy are exquisitely sensitive to oocyst challenge leading to exogenous TPI and congenitally infected calves. However, cattle which were indisputably systemically infected in their first pregnancy did not induce endogenous TPI in their subsequent pregnancy. This confirms previous results with experimental tachyzoite challenge and suggests that post-natal infection does not lead to persisting infections which can recrudesce in pregnancy.
Asunto(s)
Enfermedades de los Bovinos/parasitología , Coccidiosis/transmisión , Coccidiosis/veterinaria , Transmisión Vertical de Enfermedad Infecciosa , Neospora/patogenicidad , Complicaciones Parasitarias del Embarazo , Aborto Veterinario/parasitología , Animales , Anticuerpos Antiprotozoarios/biosíntesis , Bovinos , Enfermedades de los Bovinos/inmunología , Coccidiosis/inmunología , Femenino , Interferón gamma/biosíntesis , Intercambio Materno-Fetal , Neospora/inmunología , Oocistos/inmunología , Embarazo , Complicaciones Parasitarias del Embarazo/inmunología , VirulenciaRESUMEN
Ocean waves have multidirectional components. Most wave measurements are taken at a single point, and so fail to capture information about the relative directions of the wave components directly. Conventional means of directional estimation require a minimum of three concurrent time series of measurements at different spatial locations in order to derive information on local directional wave spreading. Here, the relationship between wave nonlinearity and directionality is utilized to estimate local spreading without the need for multiple concurrent measurements, following Adcock & Taylor (Adcock & Taylor 2009 Proc. R. Soc. A465, 3361-3381. (doi:10.1098/rspa.2009.0031)), with the assumption that directional spreading is frequency independent. The method is applied to measurements recorded at the North Alwyn platform in the northern North Sea, and the results compared against estimates of wave spreading by conventional measurement methods and hindcast data. Records containing freak waves were excluded. It is found that the method provides accurate estimates of wave spreading over a range of conditions experienced at North Alwyn, despite the noisy chaotic signals that characterize such ocean wave data. The results provide further confirmation that Adcock and Taylor's method is applicable to metocean data and has considerable future promise as a technique to recover estimates of wave spreading from single point wave measurement devices.
RESUMEN
The present work aimed to describe the current status of IVIVC/IVIVR development in the pharmaceutical industry, focusing on the use and perception of specific approaches as well as successful and failed case studies. Two questionnaires have been distributed to 13 EFPIA partners of the Oral Biopharmaceutics Tools Initiative and to the Pharmacokinetics Working Party of the European Medicines Agency in order to capture the perspectives and experiences of industry scientists and agency members, respectively. Responses from ten companies and three European Agencies were received between May 21st 2014 and January 19th 2016. The majority of the companies acknowledged the importance of IVIVC/IVIVR throughout the drug development stages and a well-balanced rate of return on investment. However, the IVIVC/IVIVR approach seemed to be underutilized in regulatory submissions. Four of the ten companies stated to have an internal guidance related to IVIVC/IVIVR modelling, whereas three felt that an overall strategy is not necessary. Successful models mainly served to support formulation development and to provide a better mechanistic understanding. There was not yet much experience with safe-space IVIVRs as well as the use of physiologically based modelling in the field of IVIVC. At the same time, the responses from both industry and agencies indicated that there might be a need for a regulatory framework to guide the application of these novel approaches. The relevance of IVIVC/IVIVR for oral IR drug products was recognized by most of the companies. For IR formulations, relationships other than Level A correlation were more common outcomes among the provided case studies, such as multiple Level C correlation or safe-space IVIVR, which could be successfully used for requesting regulatory flexibility. Compared to the responses from industry scientists, there was a trend towards a higher appreciation of the BCS among the regulators, but a less positive attitude towards the utility of non-compendial dissolution methods for establishing a successful IVIVC/IVIVR. The lack of appropriate in vivo data and regulatory uncertainty were considered the major difficulties in IVIVC/IVIVR development. The results of this survey provide unique insights into current IVIVC/IVIVR practices in the pharmaceutical industry. Pursuing an IVIVC/IVIVR should be generally encouraged, considering its high value from both industry and regulators' perspective.